Aviceda Therapeutics is winding down after a Phase 2 setback in its geographic atrophy program. A source familiar with the decision said the company had planned to advance the eye drug toward a Phase 3 filing despite the mid-stage result, but the failure drove the exit. The shutdown adds to a growing set of biotech drawdowns where clinical outcomes force rapid reprioritization and liquidity decisions. For investors and operators, it’s a reminder that late-Stage timelines can collapse quickly when efficacy or endpoints miss. The case will likely increase attention on how retinal trial design and patient selection are managed in the short runway before follow-on funding becomes difficult.